Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Reiterated by Cantor Fitzgerald

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report)'s stock had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald in a report issued on Monday, Benzinga reports. They presently have a $140.00 target price on the specialty pharmaceutical company's stock. Cantor Fitzgerald's target price points to a potential upside of 31.50% from the company's current price.

A number of other equities research analysts have also commented on the company. Royal Bank of Canada dropped their price target on Jazz Pharmaceuticals from $175.00 to $174.00 and set an "outperform" rating on the stock in a research report on Thursday, August 1st. Needham & Company LLC dropped their price target on Jazz Pharmaceuticals from $208.00 to $205.00 and set a "buy" rating on the stock in a research report on Thursday, August 1st. StockNews.com raised Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, August 1st. Morgan Stanley dropped their price target on Jazz Pharmaceuticals from $160.00 to $150.00 and set an "equal weight" rating on the stock in a research report on Friday, July 12th. Finally, Robert W. Baird dropped their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating on the stock in a research report on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $173.07.

Jazz Pharmaceuticals Trading Down 0.6 %

JAZZ traded down $0.68 during midday trading on Monday, reaching $106.46. 510,337 shares of the company were exchanged, compared to its average volume of 691,470. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $137.57. The stock has a market capitalization of $6.57 billion, a P/E ratio of 21.95, a PEG ratio of 1.34 and a beta of 0.57. The stock's 50-day simple moving average is $109.75 and its 200 day simple moving average is $112.12.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Sanctuary Advisors LLC acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $213,000. Point72 Asset Management L.P. grew its stake in Jazz Pharmaceuticals by 20,323.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 182,015 shares of the specialty pharmaceutical company's stock valued at $19,427,000 after buying an additional 182,915 shares during the last quarter. Systematic Financial Management LP grew its stake in Jazz Pharmaceuticals by 5.7% in the 2nd quarter. Systematic Financial Management LP now owns 254,330 shares of the specialty pharmaceutical company's stock valued at $27,145,000 after buying an additional 13,651 shares during the last quarter. Creative Planning grew its stake in Jazz Pharmaceuticals by 21.7% in the 2nd quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company's stock valued at $408,000 after buying an additional 680 shares during the last quarter. Finally, Algert Global LLC acquired a new position in Jazz Pharmaceuticals in the 2nd quarter valued at about $637,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.